首页> 外文期刊>Current Opinion in Cell Biology >TheEGF receptor family: spearheading a merger of signaling and therapeutics
【24h】

TheEGF receptor family: spearheading a merger of signaling and therapeutics

机译:EGF受体家族:带动信号和治疗药物的融合

获取原文
获取原文并翻译 | 示例
           

摘要

The ErbB receptor tyrosine kinases evolved as key regulatory entities enabling the extracellular milieu to communicate with the intracellular machinery to bring forth the appropriate biological response in an ever-changing environment. Since its discovery, many aspects of the ErbB family have been deciphered; with emphasis on aberration of signaling in human diseases. However, only now, with the availability of the atomic coordinates of these receptors, can we construct a comprehensive model of the mechanisms underlying ligand-induced receptor dimerization and subsequent tyrosine kinase activation. Furthermore, the recent introduction of new high-throughput screening methodologies, combined with the materialization of a systems biology perspective, reveals an overwhelming network complexity, enabling robust signaling and evolvability. This knowledge is likely to impact our view of diseases as system perturbations and resistance to ErbB-targeted therapeutics as manifestations of robustness.
机译:ErbB受体酪氨酸激酶已发展成为关键的调控实体,能够使细胞外环境与细胞内机器通讯,从而在不断变化的环境中产生适当的生物学反应。自从发现以来,ErbB家族的许多方面已经被破译。重点关注人类疾病中信号的异常。但是,只有到了现在,有了这些受体的原子坐标,我们才能构建一个由配体诱导的受体二聚化和随后的酪氨酸激酶激活机制的综合模型。此外,最近引入的新的高通量筛选方法与系统生物学观点的具体化相结合,揭示了压倒性的网络复杂性,实现了强大的信号传递和可扩展性。这种知识很可能会影响我们对疾病的看法,即系统扰动和对以ErbB为靶标的治疗方法的抵抗力(表现为健壮性)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号